Hallux
Latest round
- Series A
Last raised
- Dec 2015
Total raised
- $7.1M
Investors
- 1
About Hallux
Hallux Inc.Founded in 2012 and headquartered in Laguna Hills, US, Hallux Inc. specializes in treating onychomycosis. The company has successfully completed 2 deals, with its most recent deal occurring on November 1, 2018.Hallux Inc. specializes in the development of innovative treatments for onychomycosis, primarily through its core product, Hallux Subungual Gel (HSG). This topical antifungal therapy utilizes a novel delivery mechanism that targets the nail bed through the subungual space, an air gap accessible at the free edge of the toenail. By leveraging this route of administration, HSG aims to provide effective therapeutic concentrations directly to the infection site, addressing a significant unmet need in the treatment of this common and often painful nail disorder. The company’s target clientele includes podiatrists and dermatologists who administer the treatment, thus serving the end users—patients suffering from onychomycosis—seeking effective relief from their condition.Hallux Inc. generates revenue through the distribution of its Hallux Subungual Gel (HSG) to healthcare professionals such as podiatrists and dermatologists. These clinicians facilitate the administration of the gel to patients, positioning Hallux as a provider in a business-to-business (B2B) transaction model. Revenue is derived from direct sales to these medical practices, with pricing strategies focused on making HSG a competitive alternative to oral antifungals, while also addressing the need for affordability in the market. Given the product's innovative application method and the rigorous studies corroborating its efficacy, Hallux is positioned to foster partnerships with healthcare providers, thus reinforcing its presence in the dermatological and podiatric treatment landscape.Hallux Inc. The company aims to expand into new markets within the United States, targeting specific regions where onychomycosis is prevalent. As HSG continues through its final stages of clinical trials and moves towards regulatory approval, Hallux anticipates launching the product within the next 12 to 18 months.
Who invested in Hallux
1 investor across 1 round
See all investors in Hallux
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 16, 2015
Amount
$7.1M
Investors
Questions about Hallux
Who invested in Hallux?
Hallux has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hallux raised?
Hallux has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Hallux last raise money?
Hallux's most recent round on record is a Series A, in Dec 2015.
What does Hallux do?
Hallux is a pharmaceuticals company.
Where is Hallux headquartered?
Hallux is headquartered in Laguna Hills, US.
Which VCs invest in companies like Hallux?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Hallux's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Hallux? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.